OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas - PubMed (original) (raw)
. 2008 May;195(5):621-5; discussion 625.
doi: 10.1016/j.amjsurg.2007.12.036. Epub 2008 Apr 2.
Affiliations
- PMID: 18374895
- DOI: 10.1016/j.amjsurg.2007.12.036
OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas
MaryClare Sarff et al. Am J Surg. 2008 May.
Abstract
Background: The expression of OX40 (CD134) on activated CD4+ T cells has been associated with favorable cancer patient outcomes. Because of recent reports that sentinel lymph nodes (SLNs) may represent an immunosuppressive environment, we investigated the expression of OX40 in SLNs from patients with primary cutaneous melanoma.
Methods: Samples of peripheral blood lymphocytes and a section of 71 SLNs from 53 patients with clinically node negative melanoma were purified for CD4+ T cells, stained for OX40, and analyzed by flow cytometry.
Results: The mean percentage of OX40 on CD4 T cells in the SLNs versus peripheral blood lymphocytes was related indirectly to the T stage of the primary tumor and was decreased in ulcerated primary tumors and positive sentinel nodes.
Conclusions: The expression of OX40 on CD4+ T cells in SLNs draining primary melanomas decreased with more advanced tumor features (higher T stage, ulceration) and nodal involvement, suggesting that such tumors may have an immunosuppressive effect on the SLN microenvironment.
Similar articles
- An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma.
Schmidt CR, Panageas KS, Coit DG, Patel A, Brady MS. Schmidt CR, et al. Ann Surg Oncol. 2009 Apr;16(4):948-52. doi: 10.1245/s10434-009-0331-x. Epub 2009 Feb 5. Ann Surg Oncol. 2009. PMID: 19194758 - Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D, Mourah S, Kerob D, Verola O, Basset-Seguin N, Baccard M, Schartz N, Ollivaud L, Archimbaud A, Servant JM, Revol M, Toubert ME, Podgorniak MP, Plassa F, Porcher R, Lebbé C. Vitoux D, et al. Arch Dermatol. 2009 Oct;145(10):1105-13. doi: 10.1001/archdermatol.2009.209. Arch Dermatol. 2009. PMID: 19841396 - Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma.
Manca G, Romanini A, Pellegrino D, Borsò E, Rondini M, Orlandini C, Zucchi V, Pasqualetti F, Mariani G. Manca G, et al. J Nucl Med. 2008 Nov;49(11):1769-75. doi: 10.2967/jnumed.108.055350. Epub 2008 Oct 16. J Nucl Med. 2008. PMID: 18927334 - Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma.
Essner R. Essner R. Cancer Metastasis Rev. 2006 Jun;25(2):257-67. doi: 10.1007/s10555-006-8506-4. Cancer Metastasis Rev. 2006. PMID: 16770538 Retracted. Review. - Sentinel lymph node sampling in gynaecological cancers: techniques and clinical applications.
El-Ghobashy AE, Saidi SA. El-Ghobashy AE, et al. Eur J Surg Oncol. 2009 Jul;35(7):675-85. doi: 10.1016/j.ejso.2008.09.004. Epub 2008 Nov 2. Eur J Surg Oncol. 2009. PMID: 18980825 Review.
Cited by
- Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS, Buschow SI, IJzermans JNM, Sprengers D. Rakké YS, et al. Front Immunol. 2024 Feb 19;15:1357333. doi: 10.3389/fimmu.2024.1357333. eCollection 2024. Front Immunol. 2024. PMID: 38440738 Free PMC article. Review. - Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.
Sun X, Wang L, Li H, Jin C, Yu Y, Hou L, Liu X, Yu Y, Yan R, Xue F. Sun X, et al. Aging (Albany NY). 2021 Jun 16;13(12):16024-16042. doi: 10.18632/aging.203121. Epub 2021 Jun 16. Aging (Albany NY). 2021. PMID: 34133324 Free PMC article. - FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J. Campos Carrascosa L, et al. J Immunother Cancer. 2020 Sep;8(2):e000816. doi: 10.1136/jitc-2020-000816. J Immunother Cancer. 2020. PMID: 32900860 Free PMC article. - New pathways in immune stimulation: targeting OX40.
Alves Costa Silva C, Facchinetti F, Routy B, Derosa L. Alves Costa Silva C, et al. ESMO Open. 2020 Feb;5(1):e000573. doi: 10.1136/esmoopen-2019-000573. Epub 2020 Feb 9. ESMO Open. 2020. PMID: 32392177 Free PMC article. - Inflammation markers in cutaneous melanoma - edgy biomarkers for prognosis.
Neagu M, Constantin C, Dumitrascu GR, Lupu AR, Caruntu C, Boda D, Zurac S. Neagu M, et al. Discoveries (Craiova). 2015 Mar 27;3(1):e38. doi: 10.15190/d.2015.30. Discoveries (Craiova). 2015. PMID: 32309563 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials